Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 352

1.

Clopidogrel resistance in North Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y1 and P2Y12 gene polymorphisms.

Kar R, Meena A, Yadav BK, Yadav R, Kar SS, Saxena R.

Platelets. 2013;24(4):297-302. doi: 10.3109/09537104.2012.693992. Epub 2012 Jun 21.

PMID:
22721490
2.

The impact of CYP3A5*1/*3, PIA1/A2 and T744C polymorphisms on clopidogrel and acetylsalicylic acid response variability in Mexican population.

Isordia-Salas I, Olalde-Román MJ, Santiago-Germán D, de la Peña NC, Valencia-Sánchez JS.

Thromb Res. 2012 Sep;130(3):e67-72. doi: 10.1016/j.thromres.2012.06.024. Epub 2012 Jul 20.

PMID:
22819265
3.

P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease.

Bierend A, Rau T, Maas R, Schwedhelm E, Böger RH.

Br J Clin Pharmacol. 2008 Apr;65(4):540-7. Epub 2007 Nov 8.

4.

Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome.

Cuisset T, Frere C, Quilici J, Morange PE, Saut N, Lambert M, Camoin L, Vague IJ, Bonnet JL, Alessi MC.

Thromb Res. 2007;120(6):893-9. Epub 2007 Mar 6.

PMID:
17337040
5.

P2RY12 gene polymorphisms and effect of clopidogrel on platelet aggregation.

Galić E, Vrbanić L, Kapitanović S, Catela Ivković T, Petro D, Vuković I, Bsharat RS, Milicević Z, Vcev A, Mirat J.

Coll Antropol. 2013 Jun;37(2):491-8.

PMID:
23940995
6.

Association of CYP2C19, CYP3A5 and GPIIb/IIIa gene polymorphisms with Aspirin and Clopidogrel Resistance in a cohort of Indian patients with Coronary Artery Disease.

Arya V, Mahajan P, Saraf A, Mohanty A, Sawhney JP, Bhargava M.

Int J Lab Hematol. 2015 Dec;37(6):809-18. doi: 10.1111/ijlh.12416. Epub 2015 Aug 12.

PMID:
26264906
7.

Effect of P2Y1 and P2Y12 genetic polymorphisms on the ADP-induced platelet aggregation in a Korean population.

Kim KA, Song WG, Lee HM, Joo HJ, Park JY.

Thromb Res. 2013 Aug;132(2):221-6. doi: 10.1016/j.thromres.2013.06.020. Epub 2013 Jul 10.

PMID:
23849096
8.

Profile and prevalence of clopidogrel resistance in patients of acute coronary syndrome.

Kumar S, Saran RK, Puri A, Gupta N, Sethi R, Surin WR, Dikshit M, Dwivedi SK, Narain VS, Puri VK.

Indian Heart J. 2007 Mar-Apr;59(2):152-6.

PMID:
19122249
9.

P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose.

von Beckerath N, von Beckerath O, Koch W, Eichinger M, Schömig A, Kastrati A.

Blood Coagul Fibrinolysis. 2005 Apr;16(3):199-204.

PMID:
15795539
10.

P2Y12 receptor gene polymorphism and antiplatelet effect of clopidogrel in patients with coronary artery disease after coronary stenting.

Zoheir N, Abd Elhamid S, Abulata N, El Sobky M, Khafagy D, Mostafa A.

Blood Coagul Fibrinolysis. 2013 Jul;24(5):525-31. doi: 10.1097/MBC.0b013e32835e98bf.

PMID:
23751603
11.
12.

Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease.

Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Cavallari U, Trabetti E, Sabaté M, Jimenez-Quevedo P, Hernández R, Moreno R, Escaned J, Alfonso F, Bañuelos C, Costa MA, Bass TA, Pignatti PF, Macaya C.

Thromb Res. 2005;116(6):491-7. Epub 2005 Apr 20.

PMID:
16181985
13.

High on clopidogrel treatment platelet reactivity is frequent in acute and rare in elective stenting and can be functionally overcome by switch of therapy.

Leé S, Vargová K, Hizoh I, Horváth Z, Gulácsi-Bárdos P, Sztupinszki Z, Apró A, Kovács A, Préda I, Tóth-Zsámboki E, Kiss RG.

Thromb Res. 2014 Feb;133(2):257-64. doi: 10.1016/j.thromres.2013.11.029. Epub 2013 Dec 6.

PMID:
24359966
14.

Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene.

Staritz P, Kurz K, Stoll M, Giannitsis E, Katus HA, Ivandic BT.

Int J Cardiol. 2009 Apr 17;133(3):341-5. doi: 10.1016/j.ijcard.2007.12.118. Epub 2008 May 15.

PMID:
18485500
15.

Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.

Lepäntalo A, Virtanen KS, Reséndiz JC, Mikkelsson J, Viiri LE, Karhunen PJ, Lassila R.

Thromb Res. 2009 Jun;124(2):193-8. doi: 10.1016/j.thromres.2009.01.009. Epub 2009 Feb 15.

PMID:
19232433
17.

Impact of initial clinical presentation on clopidogrel low response.

Landel JB, Bauters A, Delhaye C, Bonello L, Sudre A, Susen S, Bauters C, Lablanche JM, Lemesle G.

Arch Cardiovasc Dis. 2013 Nov;106(11):593-600. doi: 10.1016/j.acvd.2013.06.050. Epub 2013 Sep 23.

18.

A comparison of INNOVANCE® PFA P2Y and VerifyNow P2Y12 assay for the assessment of clopidogrel resistance in patients undergoing percutaneous coronary intervention.

Jang J, Lim J, Chang K, Kim Y, Kim M, Park HI, Kim J, Shin S.

J Clin Lab Anal. 2012 Jul;26(4):262-6. doi: 10.1002/jcla.21515.

PMID:
22811359
19.
20.

Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel.

Lev EI, Patel RT, Guthikonda S, Lopez D, Bray PF, Kleiman NS.

Thromb Res. 2007;119(3):355-60. Epub 2006 Mar 6.

PMID:
16581111

Supplemental Content

Support Center